The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms. Traditional methods, such as hybridoma technology, can be time-intensive and limited in diversity. In response, Biointron has developed AbDrop™, a microfluidic, droplet-based single B cell screening platform designed to accelerate and enhance antibody discovery.
Unlike conventional approaches, AbDrop™ directly screens naturally matured individual B cells, maximizing CDR diversity by mining the entire plasma cell repertoire. This high-throughput system enables rapid identification of natively paired sequences, significantly reducing the discovery timeline to just 2–3 months.
This white paper outlines how AbDrop™ streamlines antibody discovery, providing an efficient, scalable, and precise solution for biopharmaceutical innovation.
When you’re a small biotech with big ambitions, every week counts. For Macomics ……
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, ce……
Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylate……
Your form has been submitted successfully.
DownloadYou can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
